on Theranexus (EPA:ALTHX)
Theranexus publishes its letter to shareholders
Theranexus, a French biopharmaceutical company specializing in rare neurological diseases, has announced the publication of its letter to shareholders. This document is available on the company's website, in the section dedicated to shareholders. Theranexus encourages its shareholders to subscribe to receive all official communications.
Theranexus continues to develop its innovative treatments, such as TX01, for Gaucher and Niemann-Pick type C diseases, and Batten-1, targeting juvenile Batten disease. The company has licensing agreements with international partners such as Exeltis and Biocodex. These collaborations aim to develop and commercialize their products worldwide.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news